<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3201">
  <stage>Registered</stage>
  <submitdate>16/06/2011</submitdate>
  <approvaldate>16/06/2011</approvaldate>
  <nctid>NCT01375777</nctid>
  <trial_identification>
    <studytitle>Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels</studytitle>
    <scientifictitle>A Randomized, Placebo- and Ezetimibe-controlled, Dose-ranging Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Hypercholesterolemic Subjects With a 10-year Framingham Risk Score of 10% or Less</scientifictitle>
    <utrn />
    <trialacronym>MENDEL</trialacronym>
    <secondaryid>20101154</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hyperlipidemia</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Evolocumab
Treatment: drugs - Ezetimibe
Other interventions - Placebo to Evolocumab

Placebo Comparator: Placebo Q2W - Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.

Placebo Comparator: Placebo Q4W - Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.

Active Comparator: Ezetimibe - Participants received 10 mg ezetimibe orally once a day for 12 weeks.

Experimental: Evolocumab 70 mg Q2W - Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.

Experimental: Evolocumab 105 mg Q2W - Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.

Experimental: Evolocumab 140 mg Q2W - Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.

Experimental: Evolocumab 280 mg Q4W - Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.

Experimental: Evolocumab 350 mg Q4W - Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.

Experimental: Evolocumab 420 mg Q4W - Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.


Other interventions: Evolocumab
Administered by subcutaneous injection

Treatment: drugs: Ezetimibe
Administered orally once a day

Other interventions: Placebo to Evolocumab
Administered by subcutaneous injection

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12 - LDL-C was measured using ultracentrifugation.</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in LDL-C at Week 12 - LDL-C was measured using ultracentrifugation.</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Apolipoprotein B at Week 12</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female = 18 to = 75 years of age

          -  Low density lipoprotein cholesterol (LDL-C) = 100 mg/dL and &lt; 190 mg/dL

          -  Framingham risk score of 10% or less

          -  Fasting triglycerides &lt; 400 mg/dL</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of coronary heart disease

          -  New York Heart Association (NYHA) II - IV heart failure

          -  Uncontrolled cardiac arrhythmia

          -  Uncontrolled hypertension</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>411</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD</recruitmentstate>
    <hospital>Research Site - Maroubra</hospital>
    <hospital>Research Site - Carina Heights</hospital>
    <postcode>2035 - Maroubra</postcode>
    <postcode>4152 - Carina Heights</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>AnthÃ©e</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Dour</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gozee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gribomont</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Halen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Ham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Linkebeek</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Retie</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Newfoundland and Labrador</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Aalborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Ballerup</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Vejle</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amgen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG
      145) every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on the percent change
      from baseline in LDL-C when used as monotherapy in adults with hypercholesterolemia.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01375777</trialwebsite>
    <publication>Koren MJ, Scott R, Kim JB, Knusel B, Liu T, Lei L, Bolognese M, Wasserman SM. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012 Dec 8;380(9858):1995-2006. doi: 10.1016/S0140-6736(12)61771-1. Epub 2012 Nov 6.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MD</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>